Open AccessP1030: MANIFEST‐2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE‐BLIND, ACTIVE‐CONTROL STUDY OF PELABRESIB (CPI‐0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR‐NAÏVE MYELOFIBROSIS PATIENTS
Author(s) -
Harrison C.,
Rampal R. K.,
Gupta V.,
Verstovsek S.,
Talpaz M.,
Kiladjian J.J.,
Mesa R.,
Kuykendall A.,
Vannucchi A.,
Palandri F.,
Grosicki S.,
Devos T.,
Jourdan E.,
Wondergem M. J.,
AlAli H. K.,
BuxhoferAusch V.,
AlvarezLarrán A.,
Akhani S.,
MuñozCarerras R.,
Sheykin Y.,
Colak G.,
Harris M.,
Mascarenhas J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846988.26018.ea
Subject(s) - ruxolitinib , myelofibrosis , medicine , myeloproliferative neoplasm , extramedullary hematopoiesis , essential thrombocythemia , bone marrow , polycythemia vera , gastroenterology , haematopoiesis , stem cell , biology , genetics